**QUEEN'S
UNIVERSITY
BELFAST**

Solid state ^{13}C NMR spectroscopy provides direct evidence for reaction between ethinyl estradiol and a silicone elastomer vaginal ring drug delivery system

McCoy, C. F., Apperley, D. C., Malcolm, R., Variano, B., Sussman, H., Louven, D., Boyd, P., & Malcolm, R. K. (2018). Solid state ^{13}C NMR spectroscopy provides direct evidence for reaction between ethinyl estradiol and a silicone elastomer vaginal ring drug delivery system. *International Journal of Pharmaceutics*, 548, 689-697. [10.1016/j.ijpharm.2018.07.040]. <https://doi.org/10.1016/j.ijpharm.2018.07.040>

Published in:
International Journal of Pharmaceutics

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2018 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

**Solid state ^{13}C NMR spectroscopy provides direct evidence
for reaction between ethinyl estradiol and a silicone
elastomer vaginal ring drug delivery system**

Clare F. McCoy¹, David C. Apperley², Bruce Variano³, Heather Sussman³,
Daniel Loeven³; R. Karl Malcolm^{1*}

¹School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK

²EPSRC National Solid-State NMR Service, Durham University, Durham DH1 3LE, UK

³Population Council, One Dag Hammarskjold Plaza, New York, NY 10017, USA

*Corresponding author. R. Karl Malcolm, Tel: +44 (0)28 9097 2319;

Fax: +44 (0)28 9024 7794; E-mail: k.malcolm@qub.ac.uk

Abstract

Steroid molecules have a long history of incorporation into silicone elastomer materials for controlled release drug delivery applications. Previously, based on *in vitro* release testing and drug content data, we demonstrated indirectly that the contraceptive progestin levonorgestrel chemically and irreversibly binds to addition cure silicone elastomers via a hydrosilylation reaction between its ethynyl group and the hydrosilane groups in the silicone. Here, for the first time, we report that solid state ^{13}C nuclear magnetic resonance spectroscopy provides direct evidence for the irreversible binding of ethynyl estradiol (EE) – a steroid molecule containing an ethynyl functional group – to an addition cure silicone elastomer. By preparing silicone samples containing ^{13}C -labelled ethynyl estradiol, signals in the NMR spectra could readily be assigned to both the free and bound steroid. Additional depolymerisation studies, performed on an addition cure silicone elastomer system from which the unbound EE fraction was completely extracted, further confirmed the presence of bound EE through the formation of coloured reaction mixtures resulting from the reaction of bound EE and trifluoroacetic acid. These methods will be particularly useful in the ongoing development of new steroid-releasing silicone drug delivery devices, including various vaginal ring devices for contraception, HIV prevention and multipurpose prevention technology applications.

Keywords: Covalent Binding; 17α -ethynyl-estradiol; ^{13}C -labelled; Addition cure silicone elastomer; Nuclear Magnetic Resonance; Hydrosilylation

44 **Abbreviations**

45 CDCl₃, deuterated chloroform; CP, cross-polarisation; DAC, dual asymmetric centrifuge;
46 DPV, dapivirine; EE, Ethinyl estradiol; EE-¹³C₂, 17 α -ethinyl-¹³C₂-estradiol; HIV, human
47 immunodeficiency virus; LNG, levonorgestrel; NES, Nestorone; NMR, nuclear magnetic
48 resonance; ¹³C-ssNMR, solid-state ¹³C nuclear magnetic resonance spectroscopy; TOSS,
49 total suppression of spinning sidebands; TFA, trifluoroacetic acid;

50

1. Introduction

Following first demonstration in 1966 that steroid molecules could permeate through the walls of silicone rubber containers implanted in ewes,¹ a number of steroid-releasing silicone elastomer controlled release drug delivery devices have since reached market, including the subdermal implants Norplant[®], Norplant II[®] and Jadelle[®] and the vaginal ring products Estring[®], Femring[®], Progering[®] and Fertiring[®].²⁻⁷ Several new silicone elastomer vaginal rings are currently in development, including a dapivirine-releasing ring for HIV prevention,⁸⁻¹¹ a combination dapivirine/maraviroc vaginal ring for HIV prevention,^{12,13} a dapivirine/levonorgestrel (LNG) ring for combination HIV prevention and contraception,^{14,15} a combination anastrozole/LNG ring as a novel therapy for treatment of endometriosis,¹⁶⁻¹⁸ a vaginal ring releasing the progesterone receptor modulator ulipristal acetate for contraception,^{19,20} and a Nestorone[®] (NES; segesterone acetate)/ethinyl estradiol ring for combination contraception.²¹⁻²⁴

The NES/EE vaginal ring, currently under development by the Population Council (New York, USA), comprises a silicone elastomer ring body into which two steroid-containing silicone elastomer cores are inserted – one core contains only NES and the second both NES and EE (Figure 1). The ring body is manufactured from an addition cure silicone elastomer while the drug-loaded cores are prepared using a condensation cure silicone elastomer. The cure chemistries of these silicone elastomer systems are very different, with the condensation cure silicone often preferred for preparation of drug-loaded components due to its compatibility with a wide range of chemical functional groups.¹¹ In contrast, the platinum catalyst used in addition cure silicone elastomer systems is susceptible to reaction

with certain chemical functional groups leading to inhibition of cure. During stability testing of the NES/EE vaginal ring, significant loss of EE from the ring device was observed. Since EE could be fully recovered from NES+EE cores that had not been assembled into rings, even after long term storage, the loss of EE from the ring was attributed to reaction of EE with the addition cure silicone elastomer comprising the ring body through which the drug must permeate in order to be released.

Recently, as part of preclinical development of the dapivirine/LNG vaginal ring, we reported the irreversible binding of LNG in an addition cure silicone elastomer vaginal ring, resulting in significant loss of LNG and impacting LNG *in vitro* release.^{14,15} Despite a lack of direct evidence, we hypothesized that the binding involved a hydrosilylation reaction between the LNG ethynyl group and the hydrosilane (Si-H) functionalised polydimethylsiloxane molecules in the elastomer system rendering the LNG covalently attached to the elastomer and incapable of release.¹⁵ Normally, these hydrosilane groups react with the vinyl-functionalised groups (Si-CH=CH₂) in the polydimethylsiloxane molecules as part of the curing reaction (Figure 2).

Here, we report that solid state ¹³C nuclear magnetic resonance spectroscopy (¹³C-ssNMR) provides the first direct evidence for irreversible binding of EE to an addition cure silicone elastomer. By preparing silicone elastomer samples containing ¹³C-labelled ethynyl estradiol (specifically, the ethynyl carbons are labelled and are therefore particularly sensitive to any reaction at this site), signals in the ¹³C-ssNMR spectra could readily be assigned to both the free and bound steroid.

2. Experimental Section

2.1 Materials

Addition cure silicone elastomer systems DDU-4331 (also known as MED4-4224) and DDU-4320, and condensation cure silicone elastomer system DDU-4352 (also known as MED-6603) were supplied by NuSil™ Technology LLC (Carpinteria, CA, USA). Micronised ethinyl estradiol (EE) was supplied by Bayer AG (Bergkamen, Germany). Non-micronised 17 α -ethinyl-¹³C₂-estradiol (20,21-¹³C₂ labelled; 99.1% isotopic enrichment) (EE-¹³C₂) was purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). Particle size reduction of EE-¹³C₂ was achieved by manual grinding in a mortar and pestle. Deuterated chloroform (CDCl₃, 99.8 atom % D), acetone and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Gillingham, UK).

2.2 Manufacture of Silicone Elastomer Samples

DDU-4331 silicone elastomer mixes without EE were prepared by mixing DDU-4331 Part A and DDU-4331 Part B (9:1) in a DAC150 FVK-Z Speedmixer™ (3000 rpm, 30 s) to obtain a homogeneous mixture. DDU-4320 elastomer mixes without EE were similarly prepared by mixing DDU-4320 Part A and Part B (1:1). EE-loaded (2% w/w) DDU-4331 and DDU-4320 silicone elastomer mixes were similarly prepared except with extended speedmixing at 3000 rpm for 60 s to achieve a homogeneous dispersion of the drug powders in the silicone elastomer. The elastomer mixes were poured onto a glass plate fitted with a thin-film cellulose acetate release liner and 1 mm spacers. After pouring, a second acetate release liner and glass plate were set on top and the mixtures compressed to form thin viscous films. Non-medicated DDU-4331 and DDU-4320 silicone elastomer

samples were cured in an oven at 150°C for 10 min or 90°C for 10 min, respectively. EE-¹³C₂-loaded DDU-4320 samples were cured in an oven at 90°C for 30 min. Despite adjustments to the cure conditions (final temperature and time = 130°C for > 20 h), both the EE-¹³C₂ and EE-loaded DDU-4331 silicone samples only partly cured to form gum-like consistency materials due to EE inhibition of the curing reaction.

2.3 Solvent Extraction of EE from Cured Silicone Elastomer Samples

In order to increase sensitivity of detection for any bound EE using ¹³C-ssNMR, the non-bound EE fraction was extracted from the silicone elastomer samples using organic solvent. Elastomer samples were placed in individually labelled glass vials. CDCl₃ or acetone (10–40 mL, depending on EE loading) was added to each extraction flask. Flasks were sealed and stored at ambient temperature for 24 h with periodic manual shaking. This extraction protocol was repeated three times using fresh volumes of solvent to ensure complete extraction of the non-bound EE. The elastomer samples were removed from the solvent and allowed to evaporate to dryness in preparation for ¹³C-ssNMR analysis. CDCl₃ extraction solutions were also retained for solution-state NMR analysis to verify that extraction of the non-bound EE fraction had occurred.

2.4 Trifluoroacetic Acid Depolymerisation of Cured Silicone Elastomers

Silicone elastomers are rapidly depolymerised to form a low viscosity colloidal liquid when exposed to TFA. Also, under highly acidic conditions, steroid compounds are known to react to form deeply coloured complexes.²⁵ DDU-4331 and DDU-4320 silicone elastomer samples (~ 0.2 g) – with (2 % w/w) and without EE – were placed in individual glass vials.

TFA (10 mL) was added and the flasks immediately sealed. After 24 h, any colour change was noted and photographed. The colour intensity of the depolymerised samples was used to determine whether EE or EE-¹³C₂ was detectable pre- and post-solvent extraction.

2.5 NMR Analysis

Various solution-state and solid-state ¹H-NMR and ¹³C-NMR experiments were conducted to investigate binding of EE and EE-¹³C₂ to DDU-4331 and DDU-4320 addition-cure silicone elastomer systems. In order to aid interpretation of the measured NMR spectra, MarvinSketch NMR Predictor software (ChemAxon, Budapest, Hungary) was used to produce simulated NMR spectra for EE, a model addition cure silicone elastomer and the reaction product for EE covalently bound to the silicone elastomer.

Solution-State NMR Analysis

For solution-state ¹H and ¹³C-NMR analysis, samples were dissolved, dispersed or swollen in CDCl₃. Spectra were recorded using a Bruker DPX 400 MHz NMR spectrometer (Bruker UK Ltd., Coventry, UK). Chemical shifts were recorded in ppm (parts per million) with the chemical shift of the internal reference set to 77.0 ppm for ¹³C-NMR and 7.26 ppm for ¹H-NMR with respect to CDCl₃. A series of reference spectra for the supplied APIs and DDU-4331 Part A and Part B silicone elastomer components were recorded to enable identification of characteristic API and silicone elastomer signals.

Solid-State NMR Analysis (ssNMR)

Solid-state NMR experiments were performed at the EPSRC National Solid-State NMR Service at Durham University. ^{13}C -NMR experiments were performed using either a Bruker Avance III HD spectrometer with a 4 mm (rotor o.d.) magic angle spinning (MAS) probe or a Varian VNMRS spectrometer with a 6 mm (o.d.) rotor operating at 100.6 MHz. Bruker Avance ^{13}C -NMR spectra were obtained using total suppression of spinning sidebands (TOSS) and cross-polarisation (CP) with a 4 or 10 s recycle delay, 1 or 4 ms contact time, ambient probe temperature ($\sim 25^\circ\text{C}$) and a sample spin-rate of 8 kHz. Between 250 and 20,000 repetitions were accumulated depending on the sample being analysed. ^{13}C -NMR reference spectra (EE, EE- $^{13}\text{C}_2$ and DDU-4331) were obtained using the Varian VNMRS spectrometer with TOSS (except for the EE API sample) and CP, a 1 or 30 s recycle delay, 1 or 5 ms contact time, ambient probe temperature and a spin-rate of 6 kHz. The number of scans accumulated for EE, EE- $^{13}\text{C}_2$ and DDU-4331 NMR samples varied (72, 116 and 992 repetitions) depending on the sample being analysed.

3. Results and Discussion

To aid understanding of the decreased EE content recoveries observed during long-term stability investigation of the NES/EE vaginal ring, a series of NMR studies on supplied materials (APIs and silicone elastomer components) and cured silicone elastomer samples (with and without API) were performed in order to seek direct evidence for binding of EE to the DDU-4331 silicone elastomer. In previous preclinical studies involving the dapivirine/LNG silicone elastomer ring device, we demonstrated indirect evidence – in the form of content assay data – of irreversible covalent binding between the contraceptive steroid LNG and an addition cure silicone elastomer (Nusil's DDU-4320).¹⁵ We hypothesised that the mechanism for LNG binding to the DDU-4320 silicone elastomer was via a hydrosilylation reaction between the ethynyl groups ($C\equiv C$) of the LNG with the Si-H groups on the silicone to produce a new carbon-carbon ($C=C$) double bond (Figure 2). The degree of LNG binding could be altered through modification of the temperature and time used during the silicone elastomer curing process.¹⁵ However, confirmation of the covalent binding reaction could not be confirmed using ssNMR analysis as the bound LNG fraction in the DDU-4320 silicone elastomer was below the level of detection for ssNMR. In this study, the low natural abundance of the ^{13}C isotope (1.1%) combined with the low fraction of EE that would potentially bind to the DDU-4331 silicone elastomer system would similarly make detection of new covalent bonds between the EE ethynyl groups and the silicone elastomer hydride groups extremely difficult. The use of ^{13}C -labelled EE significantly increased the sensitivity of the ^{13}C NMR (by a factor of ~90 relative to its natural 1.1% abundance), thereby improving the chances of detecting the EE + silicone reaction product.

202

203 *Sample Preparation*

204 During preparation of the 2% w/w EE and EE-¹³C₂ loaded DDU-4331 silicone samples,
205 interaction between the EE and the DDU-4331 material inhibited the silicone curing
206 reaction such that the resulting samples were tacky due to partial cure. These issues could
207 not be resolved by reducing the EE loading or altering the elastomer cure temperature and
208 time. Greater inhibition of cure was observed with the EE-¹³C₂ material. Interestingly,
209 incorporation of either 2% w/w labelled or unlabelled EE into the alternative addition cure
210 silicone elastomer DDU-4320 (previously used for manufacture of dapivirine/LNG vaginal
211 rings, where the LNG had a strong tendency to bind to the silicone elastomer) did not show
212 any obvious inhibition of cure. This confirmed that the curing issues experienced were due
213 to significant interaction between the DDU-4331 silicone system and EE.

214

215 *NMR Analysis*

216 ¹³C-NMR modelling software predicted that the purported reaction product between EE
217 and a model addition cure silicone elastomer would contain new vinylene carbons (–
218 CH=CH–) with chemical shifts in the 120–140 ppm range and disappearance of the ethynyl
219 signals at ~74 and 100 ppm (Figure 3). Signals associated with the aromatic carbons are
220 also expected to appear in 110–140 ppm region whilst the C–OH groups are predicted to
221 appear at ~80 and 155 ppm. It should be noted that these predicted spectra cannot account
222 for differences in chemical shift values associated with different stereochemical additions
223 (syn-, anti- and α-adducts) of the terminal alkyne group to the hydrosilanes of the silicone

and therefore were only intended to be used as an indicator of changes in chemical shift values for the proposed reaction product.²⁶

Solution-State NMR Reference Spectra

Solution-state ^{13}C -NMR spectra for EE, EE- $^{13}\text{C}_2$ and DDU-4331 silicone elastomer in CDCl_3 were recorded to identify reference signals. In all three solution-state ^{13}C -NMR reference spectra (Figures 4A–C), the triplet signal observed close to 77 ppm is due to the CDCl_3 solvent. In the EE ^{13}C -NMR reference spectra (Figure 4B), twenty different carbon signals associated with EE are observed. The signals at 74 and 87 ppm are assigned to the ethynyl carbons. Signals associated with C–OH carbons are observed at 80 ppm and 153 ppm, aromatic carbons in the region of 110–140 ppm, and C–C bonds in the region of 20–50 ppm. The ^{13}C -NMR reference spectra for the EE- $^{13}\text{C}_2$ (Figure 4C) displays similar chemical shifts to those of the EE reference spectra with the intense doublet signals at 74 and 88 ppm due to the ^{13}C -labelled ethynyl carbons. The presence of doublets, rather than single peaks, is due to spin-spin coupling between the neighbouring ^{13}C atoms. The apparent absence of the ~80 ppm C–OH signal in the EE- $^{13}\text{C}_2$ reference spectrum is due to its small size relative to the ^{13}C signals and/or deuterium substitution on the hydroxyl group causing an isotopic shift and resulting in the ^{13}C chemical shift of the C–OH group overlapping with the ^{13}C labelled ethynyl groups. The ^{13}C -NMR reference spectrum for the DDU-4331 silicone elastomer (Figure 4A; swollen sample in CDCl_3) displays a single large signal at ~0 ppm corresponding to the Si–CH₃ groups. The CDCl_3 solvent used during acquisition of the reference spectra did not contain tetramethylsilane (TMS) reference standard.

Solid-State NMR (ssNMR) Reference Spectra

^{13}C -ssNMR reference spectra were recorded for non-medicated cured DDU-4331 silicone elastomer, EE and EE- $^{13}\text{C}_2$ (Figures 4D–F, respectively). The narrow signals observed for the EE reference material (Figure 4B) are typical of crystalline molecules. Spinning side bands have not been suppressed in this spectrum. Broader peaks observed in the EE- $^{13}\text{C}_2$ spectrum (Figure 4F), particularly for the labelled ethynyl groups at 75 and 85 ppm, are due to strong interactions between the two neighbouring ^{13}C atoms.²⁷ As previously observed with the solution-state spectra, the ^{13}C -ssNMR reference spectrum for the cured DDU-4331 elastomer displayed a single large (Si-CH₃) signal at 1.3 ppm (Figure 4D).

Interestingly, subtle differences in ^{13}C -ssNMR spectra for the labelled and unlabelled EE materials were observed when spectra were overlaid (overlaid spectra not shown). We suspect that these spectral differences may be the result of different polymorphic forms of EE. EE is known to exist in at least two polymorphic forms with melting points at 146°C and 183°C as well as multiple pseudo-polymorphs in the form of solvates and hydrates.^{28–30} As the EE and EE- $^{13}\text{C}_2$ used in this study were obtained from two different suppliers (characterisation information was not provided), it is possible that differences in the synthetic processes caused the formation of different crystalline forms.

NMR Spectra of Silicone Elastomer Samples Containing EE or EE- $^{13}\text{C}_2$

Solvent extraction was performed on unlabelled EE-loaded silicone elastomer samples to remove the non-bound EE fraction prior to ^{13}C -ssNMR analysis. Solution-state ^1H and ^{13}C -

NMR analysis of the resulting extraction solutions showed a spectrum consistent with the chemical structure of EE (spectra not shown), confirming successful extraction of the non-bound EE portion. ^{13}C -ssNMR analysis of EE-loaded DDU-4331 samples (pre- and post-extraction) proved inconclusive, i.e. no new signals suggestive of newly formed bonds were observed.

As previously discussed, incorporation of EE into DDU-4331 resulted in significant inhibition of cure with the ^{13}C -labelled EE samples curing to a lesser extent than the unlabelled EE samples prepared with the same loading. This suggested that the EE- $^{13}\text{C}_2$ material had a greater propensity to inhibit the curing reaction of the DDU-4331 silicone elastomer and we therefore hypothesised that more EE- $^{13}\text{C}_2$ compared to unlabelled EE may be bound. From our previous studies, we know that curing conditions (temperature and time) as well as API particle size can have a significant impact on binding of steroid-type molecules to addition cure elastomers.¹⁵ Although this was considered by the authors – and was the reason that the EE- $^{13}\text{C}_2$ API was hand-milled to a finely powdered material prior to incorporation into the silicone elastomer – the lack of particle size distribution information for both EE materials meant no conclusions could be drawn. The presence of different polymorphic forms of EE, with differing solubilities could be another explanation for the different degrees of inhibition of curing observed for the ^{13}C -labelled and unlabelled EE-loaded DDU-4331 samples. As only the solubilised portion of EE participates in the covalent binding reaction with the silicone elastomer, any increase in the silicone solubility of the API would cause a subsequent increase in the amount of dissolved EE molecules

available for participation in the binding reaction, resulting in an increase in the extent that the silicone elastomer crosslinking reaction was inhibited.

Figure 5A shows the ^{13}C -ssNMR spectra for an $\text{EE-}^{13}\text{C}_2 + \text{DDU-4331}$ silicone sample before solvent extraction. The chemical shifts associated with the ^{13}C -labelled ethynyl groups are visible at 75 and 87 ppm. A second set of intense signals are observed at 125 and 153 ppm. These signals at 125 and 153 ppm are not observed in the $\text{EE-}^{13}\text{C}_2$ or DDU-4331 reference spectra (Figures 4F and 4D, respectively) and are attributed to newly-formed vinylene carbons produced from the hydrosilylation reaction between the ethynyl groups of the EE and the hydrosilane groups within the silicone elastomer (Figure 2).

Analysis of the $\text{EE-}^{13}\text{C}_2 + \text{DDU-4331}$ material following acetone extraction showed that the ethynyl signals (75 and 87 ppm) associated with the non-bound $\text{EE-}^{13}\text{C}_2$ were no longer visible in the post-extraction sample (Figure 5B), confirming that the non-bound $\text{EE-}^{13}\text{C}_2$ fraction had been successfully removed via solvent extraction. More interestingly, the new vinylene signals at 125 and 153 ppm were still observed and showed no reduction in intensity when compared to the non-extracted sample (Figure 5A), clearly indicating that they could not be removed from the silicone elastomer by solvent extraction and therefore must be bound. Therefore, Figure 5A and 5B provide direct evidence for the formation of the irreversible covalent bond between the ethynyl groups of the $\text{EE-}^{13}\text{C}_2$ and the hydrosilane groups of the DDU-4331 addition cure silicone elastomer.

In addition to the DDU-4331 system, EE-¹³C₂ loaded samples (2% w/w) were manufactured using DDU-4320 addition cure silicone elastomer. DDU-4320 has been successfully used for manufacture of a vaginal ring device containing LNG, a contraceptive steroid that also has a tendency to bind to addition cure silicones.^{14,15} With this material, no inhibition of curing was observed. ¹³C-ssNMR spectra for the EE-¹³C₂ + DDU-4320 elastomer samples showed intense ¹³C-labelled ethynyl carbons signals at 76 and 88 ppm (spectra not shown). However, no new signals indicative of EE-¹³C₂ binding were observed. In fact, no EE-¹³C₂ associated signals were observed in the spectrum of the silicone material after solvent extraction, indicating that the non-bound drug fraction had been successfully extracted and that any bound EE-¹³C₂ was below the limits of detection. On reflection, the lack of curing issues observed with the EE-¹³C₂ + DDU-4320 silicone elastomer indicated that the fraction of EE bound to the DDU-4320 was sufficiently low so as not to inhibit the curing reaction and therefore too low for detection by ssNMR. This reduced propensity for binding is most likely due to differences in the amounts of Si-H groups present in the two silicone elastomer systems.

Depolymerisation with Trifluoroacetic Acid

To supplement the NMR analysis, silicone elastomer depolymerisation experiments were performed using TFA as a qualitative measure of EE presence in cured silicone elastomer samples. TFA depolymerisation of steroid-containing silicone elastomer samples produces deeply coloured, low viscosity colloidal liquids that can be used as a rapid, highly sensitive assay for the presence of EE. The colour intensity of the EE + TFA reaction products was shown to be dependent on the initial EE concentration with a coloured reaction product

easily detected for elastomer samples containing as little as 0.05% w/w EE. Although, only qualitative in nature, the TFA depolymerisation studies appeared to be more sensitive to the presence of the EE than either solution-state or solid-state ^{13}C -NMR and provide a valuable resource for detection of residual bound EE. Depolymerisation studies were performed on a range of EE and EE- $^{13}\text{C}_2$ loaded silicone elastomer samples, both before and after solvent extraction, as a means of visually identifying the presence of bound EE.

TFA depolymerisation solutions obtained from a series of DDU-4331 and DDU-4320 elastomer samples, with and without EE- $^{13}\text{C}_2$, are shown in Figures 6A & 6B. Depolymerisation of a non-medicated DDU-4331 control sample produced a brilliant white solution (Figure 6A). This white colour is attributed to the titanium dioxide (TiO_2) reinforcing filler used in this particular silicone material. Addition of a 2% w/w EE- $^{13}\text{C}_2$ + DDU-4331 silicone elastomer samples to TFA produced a deep red-brown solution indicative of the presence of a large quantity of EE- $^{13}\text{C}_2$ (bound and non-bound) (Figure 6A). Interestingly, despite extensive solvent extraction with multiple large volumes of acetone, depolymerisation of the extracted EE- $^{13}\text{C}_2$ + DDU-4331 silicone material produced a coloured solution that was only slightly paler than that of the pre-extraction sample. This suggested that a large proportion of EE- $^{13}\text{C}_2$ was still present in the silicone elastomer, and presumably in the bound state. These results strongly support the findings of the ^{13}C ss-NMR experiments (Figure 5). A similar trend was observed for the unlabelled EE + DDU-4331 silicone samples (image not shown) despite the fact that solid-state NMR analysis of this material proved inconclusive.

The coloured reaction products obtained for a non-medicated DDU-4320 silicone elastomer sample, an EE-¹³C₂ + DDU-4320 sample pre-extraction and two EE-¹³C₂ + DDU-4320 silicone elastomer samples extracted in either CDCl₃ or acetone are shown in Figure 6B. The image shows an off-white solution for the non-medicated DDU-4320 elastomer sample, an amber coloured solution for the EE-¹³C₂ + DDU-4320 sample and pale orange coloured solutions for both the acetone and CDCl₃ extracted EE-¹³C₂ + DDU-4320 samples. The paler solutions observed for the CDCl₃ and acetone extracted samples suggest that although a significant fraction of the non-bound drug had been removed during the extraction process, a detectable fraction of EE-¹³C₂ still remained either in the bound or unbound state. As mentioned previously, no evidence of EE-¹³C₂ was observed in the ¹³Css-NMR spectra obtained for this extracted silicone material (spectra not shown) indicating that the non-bound drug fraction had been removed and any bound drug was below the limits of detection. These findings suggest that the TFA colour indicating assay is particularly sensitive to the presence of low levels of steroids when compared to either solution-state or solid-state NMR.

4. Conclusions

In this study, we demonstrate for the first time evidence for the covalent and irreversible binding of a contraceptive steroid to an addition cure silicone elastomer system. Using ¹³CssNMR analysis of DDU-4331 silicone elastomer samples containing EE-¹³C₂, we observed NMR signals due to the ¹³C-labelled ethynyl groups (75 and 87 ppm) as well as additional signals associated with newly formed ¹³C-labelled vinylene carbons (125 and 153 ppm). These new signals – not observed in the API or silicone elastomer reference

383 spectra – indicated the formation of a new C=C bond resulting from the hydrosilylation
384 reaction between the EE-¹³C₂ and the silicone elastomer. In order to confirm that these new
385 signals resulted from bound EE, the elastomer samples were subjected to acetone
386 extraction. Analysis of the extracted elastomer samples showed the complete
387 disappearance of the ethynyl-associated signals but no reduction in the new vinylene
388 signals, indicating that they could not be removed by the solvent extraction process and
389 therefore must be bound. These new vinylene chemical shifts provide conclusive evidence
390 for covalent and irreversible binding of EE-¹³C₂ to the hydrosilane groups of the DDU-
391 4331 addition cure silicone elastomer system. These results were further confirmed by the
392 findings of a TFA depolymerisation assay that demonstrated formation of strongly
393 coloured reaction products only in the presence of bound EE.

Author Information

Corresponding Author

* Karl Malcolm, School of Pharmacy, Medical Biology Centre, Queen's University
Belfast, Belfast BT9 7BL, United Kingdom. Tel: +44 (0)28 9097 2319. E-mail:
k.malcolm@qub.ac.uk

Author Contributions

All authors contributed to the design of experiments and analysis of the data. C.F.M and
D.A. conducted the experimental work. The manuscript was drafted by R.K.M and C.F.M,
with input from other authors.

Declarations of Interest

None

Acknowledgements

The work was supported by a grant to Queen's University Belfast from The Population
Council, New York, NY, USA (Grant Number PC-01-15). The authors thank the EPSRC
UK National Solid-State NMR service at Durham University for the solid-state NMR
spectra.

413 **References**

- 414 (1) Dziuk, P. J.; Cook, B. Passage of Steroids through Silicone Rubber. *Endocrinology*
415 **1966**, 78 (1), 208–211.
- 416 (2) Ballagh, S. a. Vaginal Rings for Menopausal Symptom Relief. *Drugs Aging* **2004**,
417 21 (12), 757–766.
- 418 (3) Friend, D. R. Development of Controlled Release Systems over the Past 50 Years
419 in the Area of Contraception. *J. Control. Release* **2015**, 240, 235–241.
- 420 (4) Nath, A.; Sitruk-Ware, R. Progesterone Vaginal Ring for Contraceptive Use during
421 Lactation. *Contraception* **2010**, 82 (5), 428–434.
- 422 (5) Merkatz, R. B.; Tokay, B.; Sitruk-Ware, R. L. Methods for Female Contraception:
423 A Model for Innovation in Drug Delivery Systems. *Clin. Pharmacol. Ther.* **2009**,
424 85 (5), 553–557.
- 425 (6) Buckler, H.; Al-Azzawi, F. The Effect of a Novel Vaginal Ring Delivering
426 Oestradiol Acetate on Climacteric Symptoms in Postmenopausal Women. *BJOG*
427 **2003**, 110 (8), 753–759.
- 428 (7) Al-Azzawi, F.; Buckler, H. M. Comparison of a Novel Vaginal Ring Delivering
429 Estradiol Acetate versus Oral Estradiol for Relief of Vasomotor Menopausal
430 Symptoms. *Climacteric* **2003**, 6 (2), 118–127.
- 431 (8) Baeten, J. M.; Palanee-Phillips, T.; Brown, E. R.; Schwartz, K.; Soto-Torres, L. E.;
432 Govender, V.; Mgodhi, N. M.; Matovu Kiweewa, F.; Nair, G.; Mhlanga, F.; Siva,
433 S.; Bekker, L.-G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Pather,
434 A.; Naidoo, L.; Husnik, M.; Richardson, B. A.; Parikh, U. M.; Mellors, J. W.;
435 Marzinke, M. A.; Hendrix, C. W.; van der Straten, A.; Ramjee, G.; Chirenje, Z.
436 M.; Nakabiito, C.; Taha, T. E.; Jones, J.; Mayo, A.; Scheckter, R.; Berthiaume, J.;
437 Livant, E.; Jacobson, C.; Ndase, P.; White, R.; Patterson, K.; Germuga, D.;
438 Galaska, B.; Bunge, K.; Singh, D.; Szydlo, D. W.; Montgomery, E. T.; Mensch, B.
439 S.; Torjesen, K.; Grossman, C. I.; Chakhtoura, N.; Nel, A.; Rosenberg, Z.;
440 McGowan, I.; Hillier, S. Use of a Vaginal Ring Containing Dapivirine for HIV-1
441 Prevention in Women. *N. Engl. J. Med.* **2016**, NEJMoa1506110.
- 442 (9) Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.-G.; Gama, C.; Gill, K.; Kamali,
443 A.; Kotze, P.; Louw, C.; Mabude, Z.; Miti, N.; Kusemererwa, S.; Tempelman, H.;
444 Carstens, H.; Devlin, B.; Isaacs, M.; Malherbe, M.; Mans, W.; Nuttall, J.; Russell,
445 M.; Ntshele, S.; Smit, M.; Solai, L.; Spence, P.; Steytler, J.; Windle, K.;
446 Borremans, M.; Ressler, S.; Van Roey, J.; Parys, W.; Vangeneugden, T.; Van
447 Baelen, B.; Rosenberg, Z. Safety and Efficacy of a Dapivirine Vaginal Ring for
448 HIV Prevention in Women. *N. Engl. J. Med.* **2016**, 375 (22), 2133–2143.
- 449 (10) Nel, A.; Smythe, S.; Young, K.; Malcolm, K.; McCoy, C.; Rosenberg, Z.;
450 Romano, J. Safety and Pharmacokinetics of Dapivirine Delivery from Matrix and
451 Reservoir Intravaginal Rings to HIV-Negative Women. *J. Acquir. Immune Defic.*
452 *Syndr.* **2009**, 51 (4), 416–423.

- 453 (11) Malcolm, R. K.; Boyd, P. J.; McCoy, C. F.; Murphy, D. J. Microbicide Vaginal
454 Rings: Technological Challenges and Clinical Development. *Adv. Drug Deliv.*
455 *Rev.* **2015**, *103*, 33–56.
- 456 (12) Fetherston, S. M.; Boyd, P.; McCoy, C. F.; McBride, M. C.; Edwards, K.;
457 Ampofo, S.; Malcolm, R. K. A Silicone Elastomer Vaginal Ring for HIV
458 Prevention Containing Two Microbicides with Different Mechanisms of Action.
459 *Eur. J. Pharm. Sci.* **2013**, *48* (3), 406–415.
- 460 (13) Chen, B. A.; Panther, L.; Marzinke, M. A.; Hendrix, C. W.; Hoesley, C. J.; van der
461 Straten, A.; Husnik, M. J.; Soto-Torres, L.; Nel, A.; Johnson, S.; Richardson-
462 Harman, N.; Rabe, L. K.; Dezzutti, C. S. Phase 1 Safety, Pharmacokinetics, and
463 Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind
464 Randomized Trial. *J. Acquir. Immune Defic. Syndr.* **2015**, *70* (3), 242–249.
- 465 (14) Boyd, P.; Fetherston, S. M.; McCoy, C. F.; Major, I.; Murphy, D. J.; Kumar, S.;
466 Holt, J.; Brimer, A.; Blanda, W.; Devlin, B.; Malcolm, R. K. Matrix and
467 Reservoir-Type Multipurpose Vaginal Rings for Controlled Release of Dapivirine
468 and Levonorgestrel. *Int. J. Pharm.* **2016**, *511* (1), 619–629.
- 469 (15) Murphy, D. J.; Boyd, P.; McCoy, C. F.; Kumar, S.; Holt, J. D. S.; Blanda, W.;
470 Brimer, A. N.; Malcolm, R. K. Controlling Levonorgestrel Binding and Release in
471 a Multi-Purpose Prevention Technology Vaginal Ring Device. *J. Control. Release*
472 **2016**, *226*, 138–147.
- 473 (16) Reinecke, I.; Schultze-Mosgau, M.-H.; Nave, R.; Schmitz, H.; Ploeger, B. A.
474 Model-Based Dose Selection for Intravaginal Ring Formulations Releasing
475 Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis
476 Symptoms. *J. Clin. Pharmacol.* **2016**, No. October.
- 477 (17) Rotgeri, A.; Korolainen, H.; Sundholm, O.; Schmitz, H.; Fuhrmann, U.; Prella, K.;
478 Sacher, F. Characterization of Anastrozole Effects, Delivered by an Intravaginal
479 Ring in Cynomolgus Monkeys. *Hum. Reprod.* **2015**, *30* (2), 308–314.
- 480 (18) Schultze-Mosgau, M.-H.; Waellnitz, K.; Nave, R.; Klein, S.; Kraetzschmar, J.;
481 Rautenberg, T.; Schmitz, H.; Rohde, B. Pharmacokinetics, Pharmacodynamics,
482 Safety and Tolerability of an Intravaginal Ring Releasing Anastrozole and
483 Levonorgestrel in Healthy Premenopausal Women: A Phase 1 Randomized
484 Controlled Trial. *Hum. Reprod.* **2016**, *31* (8), 1713–1722.
- 485 (19) Huang, Y.; Jensen, J. T.; Brache, V.; Cochon, L.; Williams, A.; Miranda, M. J.;
486 Croxatto, H.; Kumar, N.; Sussman, H.; Hoskin, E.; Plagianos, M.; Roberts, K.;
487 Merkatz, R.; Blithe, D.; Sitruk-Ware, R. A Randomized Study on
488 Pharmacodynamic Effects of Vaginal Rings Delivering the Progesterone Receptor
489 Modulator Ulipristal Acetate: Research for a Novel Estrogen-Free, Method of
490 Contraception. *Contraception* **2014**, *90* (6), 565–574.
- 491 (20) Brache, V.; Sitruk-Ware, R.; Williams, A.; Blithe, D.; Croxatto, H.; Kumar, N.;
492 Kumar, S.; Tsong, Y.-Y.; Sivin, I.; Nath, A.; Sussman, H.; Cochon, L.; Miranda,
493 M. J.; Reyes, V.; Faundes, A.; Mishell, D. Effects of a Novel Estrogen-Free,
494 Progesterone Receptor Modulator Contraceptive Vaginal Ring on Inhibition of
495 Ovulation, Bleeding Patterns and Endometrium in Normal Women. *Contraception*

2012, 85 (5), 480–488.

- (21) Weisberg, E.; Ayton, R.; Darling, G.; Farrell, E.; Murkies, a; O'Neill, S.; Kirkegard, Y.; Fraser, I. S. Endometrial and Vaginal Effects of Low-Dose Estradiol Delivered by Vaginal Ring or Vaginal Tablet. *Climacteric* **2005**, 8 (1), 83–92.
- (22) Fraser, I. S.; Weisberg, E.; Brache, V.; Alvarez, F.; Massai, R.; Mishell, D. R.; Apter, D.; Gale, J.; Tsong, Y. Y.; Sivin, I. Serum Nestorone® and Ethinyl Estradiol Levels, and Ovulation Inhibition in Women Using Three Different Dosage Combinations of a Nestorone Progestogen–ethinyl Estradiol Contraceptive Vaginal Ring on a Bleeding-Signaled Regimen. *Contraception* **2005**, 72 (1), 40–45.
- (23) Sivin, I.; Mishell, D. R.; Alvarez, F.; Brache, V.; Elomaa, K.; Lähteenmäki, P.; Massai, R.; Miranda, P.; Croxatto, H.; Dean, C.; Small, M.; Nash, H.; Jackanicz, T. M. Contraceptive Vaginal Rings Releasing Nestorone® and Ethinylestradiol: A 1-Year Dose-Finding Trial. *Contraception* **2005**, 71 (2), 122–129.
- (24) Croxatto, H. B.; Brache, V.; Massai, R.; Alvarez, F.; Forcelledo, M. L.; Pavez, M.; Cochon, L.; Salvatierra, A. M.; Faundes, A. Feasibility Study of Nestorone®-Ethinylestradiol Vaginal Contraceptive Ring for Emergency Contraception. *Contraception* **2006**, 73 (1), 46–52.
- (25) A Linford. Study of Steroid Color Reactions In Strong Acid. *Can. J. Biochem. Physiol.* **1957**, 35, 299–325.
- (26) Yong, L.; Kirleis, K.; Butenschön, H. Stereodivergent Formation of Alkenylsilanes: Syn or Anti Hydrosilylation of Alkynes Catalyzed by a cyclopentadienylcobalt(I) Chelate Bearing a Pendant Phosphane Tether. *Adv. Synth. Catal.* **2006**, 348 (7–8), 833–836.
- (27) Booy, K. J.; Wiegerinck, P.; Vader, J.; Kaspersen, F.; Lambregts, D.; Vromans, H.; Kellenbach, E. The Use of ¹³C Labeling to Enhance the Sensitivity of ¹³C Solid-State CPMAS NMR to Study Polymorphism in Low Dose Solid Formulations. *J. Pharm. Sci.* **2005**, 94 (2), 458–463.
- (28) Veronez, I. P.; Daniel, J. S. P.; Júnior, C. E. C.; Garcia, J. S.; Trevisan, M. G. Development, Characterization, and Stability Studies of Ethinyl Estradiol Solid Dispersion. *J. Therm. Anal. Calorim.* **2015**, 120 (1), 573–581.
- (29) Guguta, C.; Eeuwijk, I.; Smits, J. M. M.; de Gelder, R. Structural Diversity of Ethinyl Estradiol Solvates. *Cryst. Growth Des.* **2008**, 8 (3), 823–831.
- (30) Pheasant, R. Polymorphism of 17-Ethinylestradiol. *J. Am. Chem. Soc.* **1950**, 72 (9), 4303–4304.

FIGURE CAPTIONS

Figure 1. A – Photograph of Nestorone[®] / ethinyl estradiol vaginal ring; B – Schematic of ring showing dimensions and location of drug-loaded cores; C – chemical structure of the progestin Nestorone[®]; D – chemical structure of the estrogen ethinyl estradiol

Figure 2. Schematic showing the platinum-catalysed hydrosilylation reaction between ethinyl estradiol and the poly(dimethylsiloxane-co-methylhydrosilane) component of an addition cure silicone elastomer system.

Figure 3. Simulated ¹³C-NMR spectra for ethinyl estradiol and platinum-catalysed hydrosilylation reaction product between ethinyl estradiol and a model methylhydrosilane molecule.

Figure 4. A – solution state ¹³C-NMR spectrum of silicone elastomer DDU-4331; B – solution state ¹³C-NMR spectrum of ethinyl estradiol; C – solution state ¹³C-NMR spectrum of 17 α -ethinyl-¹³C₂-estradiol (20,21-¹³C₂ labelled); D – solid state ¹³C-NMR spectrum of silicone elastomer DDU-4331; E – solid state ¹³C-NMR spectrum of ethinyl estradiol; F – solid state ¹³C-NMR spectrum of 17 α -ethinyl-¹³C₂-estradiol (20,21-¹³C₂ labelled).

Figure 5. A – solid-state ^{13}C -NMR spectrum of a 2% w/w $\text{EE-}^{13}\text{C}_2$ + DDU-4331 silicone elastomer sample before acetone solvent extraction; B – solid-state ^{13}C -NMR spectrum of a 2% w/w $\text{EE-}^{13}\text{C}_2$ + DDU-4331 silicone elastomer sample after acetone solvent extraction

Figure 6. A – TFA depolymerisation solutions containing blank DDU-4331 silicone, 2% w/w $\text{EE-}^{13}\text{C}_2$ +DDU-4331 silicone and 2% w/w $\text{EE-}^{13}\text{C}_2$ +DDU-4331 extracted silicone samples; B – TFA depolymerisation solutions containing blank DDU-4320 silicone, 2% w/w $\text{EE-}^{13}\text{C}_2$ +DDU-4320 silicone, 2% w/w $\text{EE-}^{13}\text{C}_2$ +DDU-4320 deuterated chloroform extracted silicone and 2% w/w $\text{EE-}^{13}\text{C}_2$ +DDU-4320 acetone extracted silicone samples (samples listed from left to right)